Verona Pharma Set to Release Financial Updates Soon

Author: Olivia Taylor Updated: 04-15-2025 06:02 AM

Verona Pharma Announces Financial Update Schedule

Verona Pharma plc (Nasdaq: VRNA), a leading biopharmaceutical company, is poised to reveal its financial results for the first quarter that ended on March 31, 2025. The announcement is scheduled for Tuesday, April 29, 2025. Alongside the financial results, Verona Pharma will host a conference call for the investment community at 9:00 a.m. EDT / 2:00 p.m. BST. This call will not only cover their latest financial performance but will also provide insights into the company's strategic developments.

Participating in the Conference Call

Investors wishing to participate in the call can do so by dialing: +1-800-715-9871 for U.S. callers +1-646-307-1963 for international participants.

Webcast Availability

A live webcast of the event will be available on Verona Pharma’s Investors page. After the event, an audio replay will be accessible for 90 days, allowing those who could not attend the live discussion to catch up on the insights shared.

Contact Information for Further Inquiries

If you have any questions or need further information, please reach out to Verona Pharma’s dedicated team:

Verona Pharma plc
Tel: +1-844-341-9901

Victoria Stewart, Senior Director of Investor Relations and Communications
Email: IR@veronapharma.com

Argot Partners
US Investor Enquiries
Tel: +1-212-600-1902
Email: verona@argotpartners.com

Ten Bridge Communications
International / US Media Enquiries
Tel: +1-781-316-4424
Email: tbcverona@tenbridgecommunications.com

About Verona Pharma

Verona Pharma specializes in innovating therapies specifically for chronic respiratory diseases that currently lack effective treatment options. The company’s flagship product, Ohtuvayre (ensifentrine), represents a groundbreaking combination of bronchodilator and non-steroidal anti-inflammatory properties, specifically designed for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). Ensifentrine may also have relevance in managing other serious respiratory conditions like non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma, thus potentially making significant strides in patient care.

To learn more about the company and its innovative treatments, visit www.veronapharma.com.

Frequently Asked Questions

What is the purpose of the upcoming conference call?

The conference call is designed to discuss Verona Pharma's financial results for the first quarter and provide updates on the company's strategic direction.

When will Verona Pharma report its first quarter financials?

Verona Pharma is set to report its financial results on April 29, 2025.

How can investors participate in the call?

Investors can dial specific numbers provided for U.S. and international callers to join the conference call.

What is Ohtuvayre?

Ohtuvayre is Verona Pharma’s first commercial product, designed as an inhaled therapy for COPD, combining multiple therapeutic effects.

Why is this financial update important?

This update is crucial for stakeholders as it reflects the company's current performance and future strategies in addressing significant respiratory health needs.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.